Transdermal clonidine: therapeutic considerations.
Transdermal clonidine was approved by the US Food and Drug Administration in 1984 for the treatment of mild-to-moderate hypertension alone or in combination with a diuretic. Clonidine is released from the patch at a constant rate and thus displays a pharmacokinetic pattern not dissimilar to that of infusion therapy. Transdermal clonidine, like oral clonidine, is effective first- or second-line therapy for most forms of hypertension. More recently, transdermal clonidine has found alternative uses in the areas of smoking cessation, posttraumatic stress disorder, menopausal hot flashes, and alcohol and opiate withdrawal syndromes. The not infrequent development of a dermatitis, together with a substantially greater cost than oral clonidine, have been the major undoings for transdermal clonidine.
Sica
Domenic A
DA
Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298, USA. dsica@hsc.vcu.edu
Grubbs
Rebecca
R
D000279:Administration, Cutaneous; D003000:Clonidine / Q000008:administration & dosage* / Q000191:economics / Q000494:pharmacology; D003875:Drug Eruptions / Q000209:etiology; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*
D003000:Clonidine